Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;18(12):2581-2582.
doi: 10.1038/s41423-021-00787-5. Epub 2021 Nov 4.

CAR-T cell therapy: new hope for systemic lupus erythematosus patients

Xuexiao Jin  1 , Yongmei Han  1 , James Q Wang  2 , Linrong Lu  3   4
Affiliations
Comment

CAR-T cell therapy: new hope for systemic lupus erythematosus patients

Xuexiao Jin et al. Cell Mol Immunol. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Workflow of anti-CD19 CAR-T cell treatment for the SLE patient. T cells from the SLE patient were enriched from apheresis products and lentivirally transduced for CAR expression. The transduced CAR-T cells were expanded in vitro. The patient received autologous CAR-T cell infusion after lymphocyte depletion. The efficacy of the CAR-T cells in vivo was evaluated according to the B cell number and CAR-T cell percentage at different time points. The clinical disease severity evaluation for the SLE included the levels of autoantibodies, soluble complements, and proteinuria and the overall SLEDAI scores.
See this image and copyright information in PMC

Comment on

References

    1. Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385:567–9. doi: 10.1056/NEJMc2107725. - DOI - PubMed
    1. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3038–47. doi: 10.1002/art.30466. - DOI - PubMed
    1. Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11:eaav1648. - PMC - PubMed
    1. Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021;18:1896–903. - PMC - PubMed
    1. Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q, et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev Rep. 2021. 10.1007/s12015-021-10251-6. - PMC - PubMed

Publication types

MeSH terms

Substances